ALMIRRAL S.A. UNSPON ADS EACH R (ALMRY)
- Previous Close
9.28 - Open
9.28 - Bid --
- Ask --
- Day's Range
9.28 - 9.28 - 52 Week Range
8.81 - 9.28 - Volume
100 - Avg. Volume
375 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
www.almirall.com1,904
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Compare To: ALMRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALMRY
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.28%
Return on Assets (ttm)
1.23%
Return on Equity (ttm)
-2.77%
Revenue (ttm)
898.79M
Net Income Avi to Common (ttm)
-38.47M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
388.09M
Total Debt/Equity (mrq)
27.38%
Levered Free Cash Flow (ttm)
31.3M
Company Insights: ALMRY
ALMRY does not have Company Insights